Human Immunodeficiency Virus  >>  Mifeprex (mifepristone)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mifeprex (mifepristone) / Danco Laboratories
NCT00352911: Antiviral Activity and Safety of Mifepristone at 2 Doses in HIV-1 Infected Subjects

Completed
2
19
US
VGX-410 (Mifepristone), Mifeprex, Placebo for VGX-410 (Mifepristone)
VGX Pharmaceuticals, LLC
HIV Infections
06/07
11/07
2005-000728-18: An experiment of phase II open label about safety and Mifepristone vgx-410 anti-HIV activity on patients affected by HIV-1

Completed
2
15
Europe
Mifepristone, vgx-410,
AISAR ASSOCIAZIONE ITALIANA PER LO STUDIO DEGLI ANTIMICROBICI E DELLE RESISTENZE
Anti-HIV drug
 
12/05
NCT00099645: Anti-HIV Activity and Safety of 3 Different Doses of Mifepristone in HIV Infected People

Completed
1/2
48
US
Mifepristone
National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
 
08/05

Download Options